Evaluation ADHD Across the Lifespan: Evolving Needs and Novel Treatments Microlearning Activity (Part 1) Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Julie A. Carbray PhD PMHNP-BC PMHCNS-BC APRN 5 4 3 2 1 Chris Chappell 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Describe the burden, impact, and unmet needs associated with ADHD 5 4 3 2 1 Evaluate the mechanisms of action and latest clinical data associated with novel stimulants for ADHD in pediatric and adult patients 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with ADHD on a weekly basis? 10 or fewer 20 30 40 50 or more Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Which of the following statements about ADHD is TRUE? a. Adolescents with ADHD are twice as likely to be involved in teen pregnancy. b. Adults with ADHD are twice as likely to have substance abuse disorder. c. Half of children with ADHD outgrow the disorder by adulthood. d. Girls and boys are equally likely to be diagnosed with ADHD. Which of the following statements about stimulants is TRUE? a. There are no intermediate acting formulations approved for children with ADHD. b. There are no long-acting formulations approved for adults with ADHD. c. There are no long-acting formulations approved for adolescents with ADHD. d. There are no short acting formulations approved for adults with ADHD. How confident are you now in individualizing management approaches for ADHD based on specific patient characteristics? a. Very confident b. Mostly confident c. Moderately confident d. Slightly confident e. Not confident Based on my participation in this activity, I anticipate I will more often (select all that apply): Utilize different approaches for pediatric, young adult, and adult patients with ADHD Assess the ability of newer delivery options and formulations to reduce abuse potential Consider newer routes of administration in appropriate patients to optimize personalized care when available Integrate evidence-based guidelines for ADHD management while supporting the translation of clinical evidence to practice Other (fill-in) ____________ Previous
